Current News

Contact | Print version | PDF version | Send article | RSS-Feed

ITI Life Sciences signs commercialisation licence agreements with Edinburgh Instruments and Almac Sciences (Scotland) Ltd

01 Mar 2007 - ITI Life Sciences announced the signing of two Commercialisation Licence agreements based on intellectual assets created during ITI Life Sciences' Fluorescence Lifetime Assay Programme, using fluorescence lifetime for 3-D cell-based assays and other applications.
 
The first licence, signed with Almac Sciences (Scotland) Ltd, is for intellectual property relating to novel fluorescent dyes and their uses. Almac Sciences has acknowledged expertise in the provision of complex and challenging peptides and proteins. The technologies developed by the company open up exciting new opportunities in the biological and medicinal sciences and address the global requirement for ever more advanced and sophisticated polypeptides and proteins. Almac Sciences (Scotland) Ltd is part of the global Almac Group.
 
The second licence was signed with Edinburgh Instruments, which is globally recognised for the development and manufacture of high-tech fluorescence optoelectronics instrumentation. The intellectual property licensed relates to a Fluorescence Lifetime Plate Reader with high sensitivity and versatility, which Edinburgh Instruments will be selling into the High Throughput Screening and Drug Discovery Market. Work on the development of both in vitro and lab-on-a-chip based applications for this system is already ongoing with two Scottish universities. A viable assay to replace radiometric methods for protein kinases has already been demonstrated in the laboratories at Dundee University. Lifetime gives superior capabilities over Radiometric and existing Fluorescence assays